Table 2.
Summary of patient characteristics and treatment outcomes
| Case No. | PDGFRA mutation | Primary site | Disease setting | Response to imatinib | PFS on imatinib (mo) | PFS on imatinib dose escalation (mo) | PFS on 2nd-line sunitinib (mo) | OS (mo) |
|---|---|---|---|---|---|---|---|---|
| 1 | Exon 12 P567P | Stomach | Metastatic | PR | 63.8 | - | - | 65.6 |
| 2 | Exon 12 P567P | Small bowel | Metastatic | SD | 14.1 (PD) | 1.0 (PD) | 6.4 (PD) | 46.9 (dead) |
| 3 | Exon 18 Del I843 | Stomach | Localized | PR | 10.1 | - | - | 63.8 |
| 4 | Exon 12 P567P | Rectum | Metastatic | SD | 24.8 (PD) | 1.5 (PD) | 20.0 | 59.8 (deada)) |
| 5 | Exon 18 Del D842 | Stomach | Recurrent | PR | 25.2 (PD) | 5.7 (PD) | 7.3 (PD) | 51.2 (dead) |
| 6 | Exon 12 Del R560 | Stomach | Metastatic | NE | 50.9 | - | - | 53.4 |
| 7 | Exon 12 V516D | Stomach | Metastatic | NE | 44.4 | - | - | 45.8 |
| 8 | Exon 18 Del IMHD843-846 | Stomach | Recurrent | PR | 3.9 | - | - | 3.9 |
| 9 | Exon 18 Del IMHD843-846 | Stomach | Metastatic | PR | 29.5 (PD) | - | - | 46.3 |
| 10 | Exon 18 D842V | Stomach | Metastatic | PD | 4.2 (PD) | - | 14.3 (PD) | 25.2 (dead) |
| 11 | Exon 18 D842V | Stomach | Metastatic | NE | 2.7 | - | - | 32.5 |
| 12 | Exon 18 D842V | Stomach | Localized | SD | 1.4 | - | - | 28.6 |
| 13 | Exon 18 D842V | Stomach | Recurrent | NE | 0.2 (PD) | - | 0.5 (PD) | 2.6 (dead) |
| 14 | Exon 18 D842V | Stomach | Metastatic | PD | 2.6 (PD) | 0.7 (PD) | 14.6 (PD) | 23.8 |
| 15 | Exon 18 D842V | Peritoneum | Recurrent | SD | 3.8 (PD) | 4.4 (PD) | 1.9 (PD) | 24.9 |
| 16 | Exon 18 D842V | Stomach | Metastatic | NE | 0.4 | - | - | 2.8 |
| 17 | Exon 18 D842V | Stomach | Recurrent | NE | 3.9 (PD) | - | 0.7 (PD) | 8.3 (dead) |
| 18 | Exon 18 D842V | Stomach | Recurrent | PD | 0.8 (PD) | - | 4.0 (PD) | 18.7 (dead) |
PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; NE, not evaluable; PD, progressive disease.
a)
Cause of death was pneumonia which was not disease-related.